Aclaris Therapeutics (ACRS) Non-Current Deffered Revenue (2014 - 2026)

Aclaris Therapeutics' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $15.3 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 20.42% year-over-year to $15.3 million; the TTM figure through Mar 2026 stood at $15.3 million (down 20.42% YoY), while the FY2025 annual figure was $16.2 million, down 19.31% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $15.3 million, down from $16.2 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $21.2 million in Q3 2024, with the low at $15.3 million in Q1 2026.
• The 3-year median for Non-Current Deffered Revenue is $18.2 million (2025), against an average of $18.2 million.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deffered Revenue slipped 17.42% in 2025, then decreased 20.42% in 2026.
• Aclaris Therapeutics' Non-Current Deffered Revenue stood at $20.0 million in 2024, then declined by 19.31% to $16.2 million in 2025, then decreased by 5.46% to $15.3 million in 2026.
• Business Quant data shows ACRS's Non-Current Deffered Revenue at $15.3 million in Q1 2026, $16.2 million in Q4 2025, and $17.5 million in Q3 2025.